On the public citation graph

A Bibliometric Analysis of Comorbidity of Heart Failure and Type 2 Diabetes in 2015-2024

https://doi.org/10.2139/ssrn.4822553
0 signed · 48 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2016.10260openalex-extracted
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
inferredcites →https://doi.org/10.1001/jama.2018.18269openalex-extracted
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
inferredcites →https://doi.org/10.1002/phar.2839openalex-extracted
Expanded use of sodium‐glucose cotransporter 2 inhibitors: Evidence beyond heart failure with reduced ejection fraction
inferredcites →https://doi.org/10.1007/s11192-009-0146-3openalex-extracted
Software survey: VOSviewer, a computer program for bibliometric mapping
inferredcites →https://doi.org/10.1016/j.ahj.2023.08.008openalex-extracted
Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction
inferredcites →https://doi.org/10.1016/j.cardiores.2004.05.001openalex-extracted
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes
inferredcites →https://doi.org/10.1016/j.clinthera.2016.11.002openalex-extracted
SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis
inferredcites →https://doi.org/10.1016/j.cpcardiol.2023.101897openalex-extracted
Letter to the Editor: Latest FDA Approved Drug Sotagliflozin (Inpefa): A Glance at its Prospectives for Heart Failure
inferredcites →https://doi.org/10.1016/j.diabet.2022.101418openalex-extracted
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
inferredcites →https://doi.org/10.1016/j.jchf.2014.08.004openalex-extracted
Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure
inferredcites →https://doi.org/10.1016/j.jchf.2022.10.004openalex-extracted
Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure
inferredcites →https://doi.org/10.1016/j.joi.2018.03.005openalex-extracted
Examining the usage, citation, and diffusion patterns of bibliometric mapping software: A comparative study of three tools
inferredcites →https://doi.org/10.1016/s0140-6736(14)62225-xopenalex-extracted
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
inferredcites →https://doi.org/10.1016/s0140-6736(18)32261-xopenalex-extracted
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(19)31149-3openalex-extracted
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(22)01429-5openalex-extracted
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
inferredcites →https://doi.org/10.1016/s0735-1097(02)02869-3openalex-extracted
Echocardiographic detection of early diabetic myocardial disease
inferredcites →https://doi.org/10.1016/s2213-8587(14)70219-0openalex-extracted
Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people
inferredcites →https://doi.org/10.1056/nejmoa1307684openalex-extracted
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1056/nejmoa1501352openalex-extracted
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1504720openalex-extracted
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1509225openalex-extracted
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
inferredcites →https://doi.org/10.1056/nejmoa1515920openalex-extracted
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1611925openalex-extracted
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1612917openalex-extracted
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1811744openalex-extracted
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
inferredcites →https://doi.org/10.1056/nejmoa1812389openalex-extracted
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1911303openalex-extracted
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
inferredcites →https://doi.org/10.1056/nejmoa2024816openalex-extracted
Dapagliflozin in Patients with Chronic Kidney Disease
inferredcites →https://doi.org/10.1056/nejmoa2030183openalex-extracted
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
inferredcites →https://doi.org/10.1056/nejmoa2030186openalex-extracted
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
inferredcites →https://doi.org/10.1056/nejmoa2107038openalex-extracted
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
inferredcites →https://doi.org/10.1089/dia.2019.0213openalex-extracted
Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
inferredcites →https://doi.org/10.1093/eurheartj/ehv728openalex-extracted
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial
inferredcites →https://doi.org/10.1093/eurheartj/ehz486openalex-extracted
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
inferredcites →https://doi.org/10.1097/fjc.0000000000001380openalex-extracted
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
inferredcites →https://doi.org/10.1111/bph.12475openalex-extracted
Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy
inferredcites →https://doi.org/10.1111/dom.13648openalex-extracted
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis
inferredcites →https://doi.org/10.1161/cir.0000000000000691openalex-extracted
Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update
inferredcites →https://doi.org/10.1161/circulationaha.116.021887openalex-extracted
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
inferredcites →https://doi.org/10.1161/hhf.0b013e318291329aopenalex-extracted
Forecasting the Impact of Heart Failure in the United States
inferredcites →https://doi.org/10.1186/s12933-022-01512-wopenalex-extracted
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
inferredcites →https://doi.org/10.1358/dot.2021.57.2.3223386openalex-extracted
An update on dapagliflozin for the treatment of heart failure
inferredcites →https://doi.org/10.2337/dc16-0542openalex-extracted
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
inferredcites →https://doi.org/10.2337/dc22-s006openalex-extracted
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
inferredcites →https://doi.org/10.4158/cs-2017-0153openalex-extracted
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
inferredcites →https://doi.org/10.7326/m17-1362openalex-extracted
Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.7759/cureus.37388openalex-extracted
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.